Targeted cancer therapies: Clinical pearls for primary care.
作者信息
Shuel Sian L
机构信息
General practitioner in oncology in Abbotsford, BC, and Medical Education Lead of BC Cancer's Primary Care Program.
出版信息
Can Fam Physician. 2022 Jul;68(7):515-518. doi: 10.46747/cfp.6807515.
Abstract
摘要
相似文献
1
Targeted cancer therapies: Clinical pearls for primary care.靶向癌症治疗：初级保健的临床要点
Can Fam Physician. 2022 Jul;68(7):515-518. doi: 10.46747/cfp.6807515.
2
Detecting cancer: Pearls for the primary care physician.癌症检测：基层医疗医生的实用诀窍
Cleve Clin J Med. 2016 Jul;83(7):515-23. doi: 10.3949/ccjm.83a.15124.
3
Radiotherapy: Clinical pearls for primary care.放射治疗：基层医疗的临床要点
Can Fam Physician. 2021 Oct;67(10):753-757. doi: 10.46747/cfp.6710753.
4
Adverse events of targeted therapies reported by patients with cancer treated in primary care.在初级保健中治疗的癌症患者报告的靶向治疗的不良反应。
Eur J Gen Pract. 2020 Dec;26(1):202-209. doi: 10.1080/13814788.2020.1846713.
5
Long-Term Care of the Abdominal Organ Transplant Recipient: Pearls for the Primary Care Provider.腹部器官移植受者的长期护理：初级保健提供者的经验之谈
Med Clin North Am. 2016 May;100(3):xvii-xviii. doi: 10.1016/j.mcna.2016.03.003.
6
The Top 10 Pulmonary Pearls for Primary Care Physicians.基层医疗机构医师必读的十大肺部要点。
Mayo Clin Proc. 2018 Aug;93(8):1131-1138. doi: 10.1016/j.mayocp.2018.06.011.
7
Geographic Variations and Time Trends in Cancer Treatments in Taiwan.台湾癌症治疗的地理差异与时间趋势。
BMC Public Health. 2017 Aug 2;18(1):89. doi: 10.1186/s12889-017-4615-y.
8
Evidence-based medicine: the pearls in the medical literature.循证医学：医学文献中的精华
JAAPA. 2009 Jul;22(7):8. doi: 10.1097/01720610-200907000-00001.
9
Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.意大利南部地区癌症治疗中生物和非生物靶向治疗的使用情况及费用：5 年数据。
Clin Drug Investig. 2018 Mar;38(3):269-278. doi: 10.1007/s40261-017-0591-3.
10
Adverse Hair Reactions to New Targeted Therapies for Cancer.癌症新型靶向治疗药物的不良毛发反应
Actas Dermosifiliogr (Engl Ed). 2019 Apr;110(3):182-192. doi: 10.1016/j.ad.2018.10.019. Epub 2019 Feb 2.
引用本文的文献
1
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.肿瘤微环境中肿瘤相关巨噬细胞的双重作用及治疗靶点
Signal Transduct Target Ther. 2025 Aug 25;10(1):268. doi: 10.1038/s41392-025-02325-5.
2
ARID1A: gene, protein, and function in endometrial cancer.ARID1A：子宫内膜癌中的基因、蛋白质及功能
Oncogene. 2025 Aug 18. doi: 10.1038/s41388-025-03539-1.
3
Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.弥合寄生虫作为先进癌症治疗方法的多样化应用之间的差距：当前进展与未来方向。
Infect Agent Cancer. 2025 Jul 29;20(1):53. doi: 10.1186/s13027-025-00679-7.
4
The Role of Axl Inhibition and Immune Checkpoint Blockade in Non-small Cell Lung Cancer: Current Understanding and Treatment Strategies.Axl抑制和免疫检查点阻断在非小细胞肺癌中的作用：当前认识与治疗策略
Cancer Diagn Progn. 2025 Jun 30;5(4):417-428. doi: 10.21873/cdp.10455. eCollection 2025 Jul-Aug.
5
Design, Synthesis, and Biological Evaluations of a Novel Resveratrol-Type Analogue Against VEGF.一种新型白藜芦醇类抗血管内皮生长因子类似物的设计、合成及生物学评价
Molecules. 2025 May 27;30(11):2345. doi: 10.3390/molecules30112345.
6
Molecular mimicry between parasites and cancer: a novel approach for developing cancer vaccines and therapeutic antibodies.寄生虫与癌症之间的分子模拟：开发癌症疫苗和治疗性抗体的新方法。
Cancer Immunol Immunother. 2025 May 22;74(7):212. doi: 10.1007/s00262-025-04069-1.
7
Nano-immunotherapy: Merging immunotherapy precision with nanomaterial delivery.纳米免疫疗法：将免疫疗法的精准性与纳米材料递送相结合。
iScience. 2025 Mar 30;28(5):112319. doi: 10.1016/j.isci.2025.112319. eCollection 2025 May 16.
8
Living with chronic myelogenous leukemia in rural communities: Exploring factors related to tyrosine kinase inhibitors adherence with a mixed methods approach.农村社区慢性髓性白血病患者的生活状况：采用混合研究方法探索与酪氨酸激酶抑制剂依从性相关的因素。
J Rural Health. 2025 Mar;41(2):e70028. doi: 10.1111/jrh.70028.
9
The Potential of Peptide-Based Inhibitors in Disrupting Protein-Protein Interactions for Targeted Cancer Therapy.基于肽的抑制剂在破坏蛋白质-蛋白质相互作用以进行靶向癌症治疗中的潜力。
Int J Mol Sci. 2025 Mar 28;26(7):3117. doi: 10.3390/ijms26073117.
10
Harnessing exosomes for targeted drug delivery systems to combat brain cancer.利用外泌体构建靶向给药系统以对抗脑癌。
Cancer Cell Int. 2025 Apr 15;25(1):150. doi: 10.1186/s12935-025-03731-z.
本文引用的文献
1
Molecularly targeted cancer therapy: some lessons from the past decade.分子靶向癌症治疗：过去十年的一些经验教训。
Trends Pharmacol Sci. 2014 Jan;35(1):41-50. doi: 10.1016/j.tips.2013.11.004. Epub 2013 Dec 19.
2
Targeted drug delivery for cancer therapy: the other side of antibodies.靶向药物输送在癌症治疗中的应用：抗体的另一面。
J Hematol Oncol. 2012 Nov 9;5:70. doi: 10.1186/1756-8722-5-70.
3
Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.帕妥珠单抗：用于治疗 HER2 阳性转移性乳腺癌的一线药物。
Drugs. 2012 Feb 12;72(3):353-60. doi: 10.2165/11209000-000000000-00000.
4
Progress in cancer chemotherapy with special stress on molecular-targeted therapy.癌症化疗的进展，特别强调分子靶向治疗。
Jpn J Clin Oncol. 2010 Sep;40(9):855-62. doi: 10.1093/jjco/hyq035. Epub 2010 Jul 22.
5
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.贝伐单抗：一种用于治疗实体恶性肿瘤的血管生成抑制剂。
Clin Ther. 2006 Nov;28(11):1779-802. doi: 10.1016/j.clinthera.2006.11.015.
6
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.表皮生长因子受体抑制剂治疗期间皮肤毒性的临床体征、病理生理学及管理
Ann Oncol. 2005 Sep;16(9):1425-33. doi: 10.1093/annonc/mdi279. Epub 2005 Jul 12.
Zotero 插件